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Chemoattractants control selective leukocyte homing via interactions with a dedicated 
family of related G protein-coupled receptor (GPCR). Emerging evidence indicates that 
the signaling activity of these receptors, as for other GPCR, is influenced by allosteric 
modulators, which interact with the receptor in a binding site distinct from the binding site 
of the agonist and modulate the receptor signaling activity in response to the orthosteric 
ligand. Allosteric modulators have a number of potential advantages over orthosteric 
agonists/antagonists as therapeutic agents and offer unprecedented opportunities 
to identify extremely selective drug leads. Here, we resume evidence of allosterism in 
the context of chemoattractant receptors, discussing in particular its functional impact 
on functional selectivity and probe/concentration dependence of orthosteric ligands 
activities.
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iNTRODUCTiON
G protein-coupled receptors (GPCRs) are the largest family of cell-surface receptors encoded by the 
human genome and are involved in most pathophysiological aspects (1, 2). GPCRs fulfill the vital 
biological function of transducing effects of extracellular signals (photons, lipids, neurotransmitters, 
proteins, etc.) across the cellular membrane into the cytosolic space via the activation of dedicated 
signaling pathways. Physiologically, when the extracellular signal interacts with the so-called “orthos-
teric binding site” of a GPCR, a conformational change occurs that conveys the signal through the 
plasma membrane, thus triggering intracellular signaling cascades via heterotrimeric G proteins and 
other signal transducers (3). Because of the involvement of GPCRs in a plethora of physiological and 
pathological processes, this receptor family includes most of the targets of actual and potential drugs 
(1, 4, 5), thus making GPCRs the largest class of targets for drug discovery.
Selective leukocyte homing via chemoattractant/receptor interactions is pivotal for the organi-
zation of the immune system and for protection against infectious diseases. Chemoattractants are 
also key players in the development and exacerbation of immunomediated pathological conditions, 
such as allergic responses, autoimmune diseases, and other acute and chronic inflammatory disor-
ders, and their fine regulation plays a crucial role for the development of an appropriate immune 
Abbreviations: ACKRs, atypical chemokine receptors; ANCA, anti-neutrophil cytoplasmic antibodies; C5aR, activated com-
plement component 5a receptor; FPR, formyl peptide receptor; GPCRs, G protein-coupled receptors; LTB4R, leukotriene B4 
receptor; NAMs, negative allosteric modulators; NOD, non-obese diabetic; PAFR, platelet-activating factor receptor; PAMs, 
positive allosteric modulators; SAMs, silent allosteric modulators; TM, transmembrane helices; WHIM, warts, hypogamma-
globulinemia, infections, and myelokathexis.
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response (6). Leukocyte chemoattractant ligands include a 
structurally diverse collection of bioactive molecules, including 
lipids (leukotrienes, prostaglandins, and platelet-activating fac-
tor), peptides (formyl peptides), and proteins (chemokines, non-
chemokine cytokines, and defensins). Chemoattractant ligands 
are recognized by a distinct GPCR family categorized into 
classical chemoattractant and chemokine GPCRs on the basis of 
their ligands. Classical chemoattractant GPCRs include formyl 
peptide receptors (FPR and its variants), the platelet-activating 
factor receptor (PAFR), activated complement component 5a 
receptor (C5aR), and leukotriene B4 receptors (LTB4R and its 
variants). Chemokine GPCRs are subcategorized in four families 
termed CCR, CXCR, CX3CR, and XCR based on the relative 
positioning of conserved cysteine residues in the N-terminal 
domain of their mature ligands. So far, roughly 50 chemokines 
and at least 18 chemokine GPCRs have been identified in humans 
(7). Beyond chemokine GPCRs, a group of atypical chemokine 
receptors (ACKRs), which appear to shape chemokine gradients 
and dampen inflammation by scavenging chemokines in a 
G protein-independent β-arrestin-dependent manner, has also 
recently been recognized (8).
G protein-coupled receptors are integral membrane proteins 
in constant equilibrium between various functionally distinct 
conformational states, and this equilibrium is influenced by their 
exogenous and endogenous ligands (9). Exogenous GPCR ligands 
can bind to their receptor either competitively (orthosterically) by 
interacting with the same receptor binding site as the endogenous 
agonist and are classified as agonists, antagonists, and/or inverse 
agonists, based on their effects on G protein signaling. Allosteric 
modulators induce biological responses through interaction 
with a distinct binding site and can directly modulate binding 
of orthosteric ligands and their signaling activity. Allosteric 
modulators have a number of potential advantages over orthos-
teric agonists/antagonists as therapeutic agents, including greater 
selectivity for receptor subtypes and the opportunity to identify 
synthetic ligands for a receptor whose orthosteric binding site 
has been proven to be chemically intractable, as for glucagon-like 
peptide 1 receptor agonists (10, 11). However, implications and 
potentials of allosteric modulation in chemoattractant GPCR 
biology are far to be fully elucidated, and this review aims at 
highlighting emerging concepts and open questions.
ALLOSTeRiSM AND GPCR SiGNALiNG
The ternary complex model for GPCRs activation, which describes 
a receptor that moves laterally in the cell membrane to physically 
couple to a trimeric G protein after activation by an agonist, 
only accounts for part of the complexity of GPCR-signaling 
system (12). Ligand binding in the extracellular compartment 
activates intracellular signals propagated not only through 
G proteins, but also through β-arrestin and accessory proteins 
binding, and literature (13) proposes more complex models for 
receptor activation accounting for multiple signaling states with 
several conformations stabilized by both different ligands and by 
single ligand in different conditions. Functional selectivity, probe 
dependence, and concentration dependence are all properties 
of chemoattactant receptors’ signaling unraveling aspects of the 
complex processes underlying receptor activation.
Concentration-dependence signaling accounts for different 
concentrations of the same ligand inducing different receptor 
responses (14). The typical bell-shaped dose–response curve 
of chemoattractant-dependent cell migration represents a clear 
example of this behavior and is particularly relevant in the biol-
ogy of chemoattractant receptors as they are sensitive to ligand 
gradients. As an example, high concentrations of a chemokine 
ligand, such as CXCL12, have been reported to induce inverse 
migration of CXCR4 expressing cells in several in vitro and ex vivo 
models (15, 16). The biological significance of this phenomenon, 
defined as chemorepulsion or fugitaxis, has been defined in the 
specific context of T-cell trafficking during thymic migration (17). 
A number of explanations have been proposed, including the exist-
ence of high- and low-affinity-binding sites for the same ligand 
and the concentration-dependent dimerization/oligomerization 
of the cognate receptor (18, 19).
A second property of GPCR signaling is functional selectiv-
ity or “biased signaling,” an effect mainly observed for class 
A and C GPCRs (20), which refers to the ability of different 
ligands to activate a certain intracellular signaling pathway 
over another on a given receptor (21). At least three elements 
contribute to make functional selectivity a key element for che-
moattractants: (i) spatiotemporal and tissue-specific expression 
of chemoattractant receptors and their ligands; (ii) modulation 
of receptor activity by proteins interacting with the receptor 
(or receptor oligomers) or making heterocomplexes with 
the ligand; (iii) receptor-intrinsic biased signaling triggered 
by different chemokines binding to the same receptor (22). 
Indeed, several chemoattractant receptors are activated by 
multiple endogenous ligands, which may activate distinct 
signaling pathways through the same receptor, thus suggesting 
the existence of different “active” conformations of the receptor 
associated with a particular repertoire of intracellular proteins 
(23). Consistent with this, several examples of chemoattractant 
receptors with biased signaling have been reported. This is par-
ticularly prominent in receptors with a large number of ligands, 
such as CCR1, which has partial agonists (CCL14, CCL15, 
and CCL23) becoming fully active after processing of their 
extended N-terminal domain (24, 25), β-arrestin-biased ligands 
(CCL5, CC15, and CCL23) (26), and G protein-biased agonists 
(CCL5) (26). CCR7 is activated by CCL19 and CCL21, which 
are equivalent for G protein signaling but differ in their GRK 
and β-arrestin engagement (27, 28), while all CCR2 ligands 
have balanced G protein/β-arrestin signaling but interestingly 
CCL8 is biased for signaling to β-arrestin2 vs. β-arrestin1 (29). 
Most importantly, there is also clear evidence of the biological 
relevance of biased signaling in chemokine receptors, as the 
warts, hypogammaglobulinemia, infections, and myelokathexis 
(WHIM) syndrome is caused by mutations deleting the CXCR4 
C-terminal domain which generate receptor variants acting as 
G protein-biased receptors because compromised in their ability 
to engage β-arrestin for the absence of relevant phosphorylation 
residues (30). Finally, in the chemokine field, ACKR represents 
a striking evidence of β-arrestin-biased signaling receptors 
(31–33). Thus, not only chemokine receptors are complex 
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signaling molecules able to engage different signaling pathways, 
but different ligands have biased signaling effects, and this has 
become of particular relevance considering the chemokine sys-
tem promiscuity. In this context, the property of allosteric ligands 
of interacting with ligand-bound receptors introduces a further 
element of complexity and, not surprisingly, the action of an 
allosteric modulator may differentially affect receptor functions 
depending on which agonist is used as activating probe. Probe 
dependence, a phenomenon widely reported for chemokine 
receptors (6), is therefore a clear consequence of the cooperativity 
between orthosteric and allosteric sites. An interesting example 
of the probe-dependent behavior of allosteric modulators has 
been reported for a series of CCR1 ligands showing opposite 
effect on the affinity of two endogenous receptor ligands with 
not overlapping binding sites. In fact, these metal ion chelating 
compounds originally selected as full CCR1 agonists were found 
to act as allosteric enhancers of CCL3 binding while displacing 
CCL5 binding at the orthosteric site (34). Similarly, AMD3100 
acts as a potent allosteric inhibitor of CXCL12-induced CXCR4 
activation but does not affect receptor-mediated response to 
CXCL12 peptide fragments with agonistic properties (35). 
Allosteric-biased modulation on GPCRs can also occur between 
G proteins and other signaling effectors, such as β-arrestins, as 
demonstrated in the case of a CXCR4 allosteric modulator (36). 
If, on the one hand, probe dependence gives a very high hurdle 
to the characterization of allosteric ligands; on the other hand, it 
offers unprecedented opportunities to identify extremely selec-
tive drug leads, allowing a fine modulation of receptor-activated 
signals in complex biological systems.
As discussed, GPCRs are allosteric proteins and G proteins 
behave as natural endogenous allosteric modulators of this class 
of receptors. The progressive characterization and identification 
of functionally conserved allosteric sites in different GPCRs 
unavoidably raise the question whether these sites may represent 
binding motifs for unknown ligands, physiologically behaving as 
allosteric receptor modulators (37). In this perspective, a huge 
number of natural substances belonging to diverse chemical 
classes (ions, lipids, and peptides) have been reported as putative 
endogenous allosteric modulators of GPCRs. Our studies have 
highlighted the functional relevance of a minor pocket conserved 
in both classical chemoattractant and chemokine GPCRs account-
ing for the fine regulation of receptors activation and not involved 
in the orthosteric ligand binding (38) (see below). The existence 
of specific endogenous ligands behaving as non-competitive 
allosteric modulators interacting at this minor pocket represents 
an attractive work hypothesis.
While offering unprecedented opportunities for the design of 
highly selective pharmacological tools, the allosterism concept 
implies a profound revision of the entire drug discovery process 
having impact on the design and characterization of novel lead 
candidates targeting the GPCR family. From the structural 
point of view, biased allosteric modulation, probe dependence, 
and ligand cooperativity require the ability to model multiple 
conformational states in the presence of different ligands that still 
represents a major hurdle for the rational design of drugs. Several 
independent studies have shown how subtle structural and 
electronic modifications in a class of allosteric GPCRs modulators 
may result in dramatic changes of the biological activity, thus 
limiting the possibilities to conduct large and efficient lead 
optimization programs (39–41). In this context, the synthesis 
of focused iterative libraries with limited structural variability is 
often more efficient than the classical high-throughput screening 
of large diverse chemical libraries. Furthermore, the biological 
characterization of a new class necessitates a multistep approach 
that carefully takes into account the multifaceted characteris-
tics of the allosteric modulation mechanisms. When multiple 
endogenous ligands for the target receptor are reported, as for 
chemokine receptors, several in  vitro assays using different 
probes are recommended for a correct evaluation of probe-
dependent effects. The complexity further increases when biased 
signal is considered, in fact the development of several functional 
assays in relevant cellular systems is crucial to assess the effect 
of selected leads on the different signaling pathways including 
non G protein-mediated signaling. In many cases, the ideal drug 
profile for the treatment of a specific pathological condition may 
be scarcely predicted a priori; thus, the ultimate goal of a lead 
optimization program should be the selection of several chemical 
classes with distinct in vitro (probe dependence and functional 
selectivity) profiles to be in parallel evaluated in relevant in vivo 
models.
NeGATive AND POSiTive ALLOSTeRiSM
Receptor allosteric sites are normally devoted to bind endog-
enous mineral cations, such as sodium, calcium, zinc, and 
magnesium, or synthetic drugs (42). From a structural point of 
view, allosteric modulators can be unrelated to the structure of 
competitive agonists or antagonists. Within the A class GPCR 
family, orthosteric binding sites are highly conserved and amino 
acid sequences necessary for the binding of endogenous ligands 
are retained, while allosteric modulator binding sites show a 
great structural diversity, thus displaying a high selectivity for 
a receptor subtype (43). Allosteric modulators can promote or 
reduce the binding affinity of orthosteric ligands via conforma-
tional coupling between the orthosteric and allosteric binding 
sites, or modulate efficacy by altering the functional response of 
the receptor to orthosteric ligand binding, thus resulting in posi-
tive, negative, or neutral effects on receptor activation (Figure 1). 
Negative allosteric modulators (NAMs) bind at the allosteric site 
to inhibit the efficacy or affinity of agonists to the orthosteric site 
and do not have any intrinsic agonist efficacy. This effect occurs 
either by stabilizing an inactive conformation of the receptor 
or by raising the energy barrier requested to activate the recep-
tor (44). NAMs produce rightward and/or downward shifts in 
agonist concentration–response curves. This can result from the 
NAM decreasing agonist affinity (at equilibrium) by stabilizing a 
lower affinity receptor conformation, from the NAM increasing 
the energy barrier for transition to the active state, or both. The 
degree of shift is finite and reaches a maximum as the allosteric 
site is fully occupied by the NAM, differently from what occurs 
with competitive orthosteric antagonists which produce ever 
greater shifts at increasing concentrations with no theoretical 
limit, because of the direct competition for the agonist-binding 
site (44). Positive allosteric modulators (PAMs) bind to their 
FiGURe 1 | Allosteric modulators effects on orthosteric agonist efficacy and potency. Positive (PAM) and negative (NAM) allosteric modulators modulate 
the affinity and/or the efficacy of orthosteric agonists, while silent allosteric modulators (SAM) have no effect on the affinity and/or efficacy mediated by the 
orthosteric agonist. Abbreviations used: OA, orthosteric agonist; NAM, negative allosteric modulator; PAM, positive allosteric modulator; SAM, silent allosteric 
modulator.
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allosteric site and either promote the binding of the agonists at 
the orthosteric site or lower the energy barrier necessary to shift 
the receptor to the active conformation. PAMs do not display 
any activity or pharmacological effect in the absence of the endo/
exogenous agonists, but when combined with an orthosteric 
agonist, they increase its efficacy, thus improving the overall 
side-effect profile of the agonist. From the mechanistic perspec-
tive, NAMs and PAMs can exert their effects either by altering 
the binding affinity of the orthosteric ligand or by inducing a 
conformational change that affects the ability of the ligand/recep-
tor complex to propagate the stimulus to intracellular proteins. 
Finally, neutral allosteric ligands, previously referred to as silent 
allosteric modulators (SAMs), have no effect on orthosteric 
agonists affinity or efficacy but are able to act as competitive 
antagonists at the same allosteric site and block PAM or NAM 
activity, and are often used to confirm the receptor engagement 
by NAMs or PAMs (45).
ALLOSTeRiC MODULATiON OF 
CHeMOKiNe ReCePTORS
The most relevant efforts to develop chemokine receptor inhibi-
tors have been focused on drugs blocking HIV infection (see 
Table 1). This effort led to the registration as anti-HIV drug of 
the CCR5 antagonist Maraviroc (Celsentri/Selzentry; Pfizer), 
while the CXCR4 antagonist Plerixafor (Mozobil/AMD-3100; 
Genzyme), originally developed as a second anti-HIV drug, was 
subsequently assessed as an hematopoietic stem cell mobilizer 
and is now indicated in combination with G-CSF to mobilize 
stem cells to the peripheral blood in autologous transplantation in 
patients with non-Hodgkin’s lymphoma and multiple myeloma. 
Conversely, a number of clinical trials of chemokine receptor 
antagonists for immunomediated diseases have been disappoint-
ingly unsuccessful, generally due to a lack of efficacy in Phase 
II for inappropriate target selection and/or insufficient receptor 
TABLe 1 | Selected inhibitors of chemokine and chemoattractant receptors.
Name Structure MoA Company Stage indication
Cinacalcet
NF
FF
H CaSR
PAM
Amgen M End-stage renal disease
Plerixafor (AMD3100)
N
H
N
N
H
NH
N
N
H
NH
N
H
CXCR4
NAM
Genzyme M Bone marrow transplantation
Maraviroc F F
O NH
N
N
N
N
CCR5
NAM
Pfizer M HIV
Reparixin (DF1681Y)
O
N
S
O
O
H CXCR1
NAM
Dompé farmaceutici III β-cell transplantation
Ladarixin (DF2156A)
O
N-
S
O
O
O
S
O
O
F
F
F
Na
+ CXCR2
CXCR2
NAM
Dompé farmaceutici II Onset type 1 diabetes
Navarixin
O N N
OH O
N
O O
H H
CXCR2
NAM
Pharmacopeia D COPD
PMX-53
NH2
N
NH
O
NH
O
NH
O
N O
NH
O
NH
O
NH
O
N
H
NH2
H
H
H
H
H
H
C5aR antagonist Cephalon (now Arana) D Immunity inflammation
Avacopan (CCX-168)
N
O
NH
NHO
F
F
F F
C5aR antagonist ChemoCentrix III ANCA vasculitis
DF2593A
O
NH
S
O
O
F
F
F
O
N
+
H
Cl-
C5aR NAM Dompé farmaceutici P Pain
CaSR, calcium-sensing receptor; HIV, human immunodeficiency virus; COPD, chronic obstructive pulmonary disease; ANCA, anti-neutrophil cytoplasmic antibodies; M, marketed; P, 
preclinical; D, discontinued.
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coverage. However, new clinical programs in focused indications 
are ongoing, setting the premises for a better understanding of the 
therapeutic potential of these important targets. Among these, 
29 drugs are reported as “allosteric modulators of chemokine 
receptors,” three of them being in Phase II and two in Phase III of 
development (Thomson Reuters Cortellis Business Intelligence; 
https://cortellis.thomsonreuterslifesciences.com).
Reparixin (formerly known as repertaxin) and ladarixin 
represent the first examples of non-competitive allosteric modu-
lators of chemokine receptors, showing the ability to behave as 
NAMs of CXCR1/CXCR2 without affecting the cognate ligand 
binding affinity. Interleukin-8 (IL-8; CXCL8) and related ELR+ 
CXC chemokines are able to interact with CXCR1 and CXCR2 at 
a different degree, with IL-8 and CXCL6 being potent agonists for 
both CXCR1 and CXCR2, whereas the other chemokines show a 
higher selectivity degree toward the CXCR2 subtype. CXCR1 and 
CXCR2 are largely expressed on PMNs but also T lymphocytes 
and natural killer cells, and play a key role in leukocyte trafficking 
in inflammatory conditions (46–49). The contribution of IL-8 
and its CXCR1/CXCR2 receptors to the physiopathology of sev-
eral acute and chronic inflammatory conditions, from ischemia/
reperfusion injury to chronic obstructive pulmonary disease 
and fibrosis, is well assessed by the scientific literature (50–53). 
Modulators of CXCR1 and CXCR2 function may be useful to treat 
chronic inflammatory conditions in humans (46). Reparixin was 
the first known non-competitive allosteric inhibitor of IL-8 recep-
tors, with a 400-fold higher efficacy in inhibiting CXCR1 activity 
than CXCR2. Its molecular mechanism of action was thoroughly 
investigated showing that the molecule binds CXCR1 in an allos-
teric site spanning between transmembrane helices (TM) 1, 3, 6, 
and 7 and inhibits the signaling triggered by IL-8 without affect-
ing its binding to the receptor (54). The efficacy of the molecule in 
preventing PMN recruitment and associated tissue damage was 
demonstrated in experimental models of ischemia/reperfusion 
injury (2, 55, 56) and organ transplantation (57), thus paving the 
way to clinical development. The molecule recently completed 
the first Phase III trial aimed at demonstrating its efficacy in the 
prevention of graft loss in allogeneic pancreatic islet transplanta-
tion, thus confirming the validity of the approach. The knowledge 
of reparixin molecular mechanism of action paved the way to a 
rational design approach to identify potent dual CXCR1/CXCR2 
inhibitors with improved pharmacokinetic properties suitable 
for long term administration (41). Ladarixin (DF 2156A), the 
second clinical candidate in this class, is a highly potent CXCR1 
and CXCR2 inhibitor (IC50 =  0.1  nM) that is able to block in 
a probe-independent manner the receptor activation process. 
Interestingly, mechanistic studies support the rationally derived 
binding mode hypothesis, thus confirming that the allosteric site 
is conserved among the two receptor subtypes. The binding mode 
of the molecule with CXCR1 and CXCR2 is in keeping with the 
concept that allosteric sites in the TM domains of GPCRs could 
represent valuable targets for selective allosteric inhibitors able 
to finely modulate receptor signaling, and suggests their thera-
peutic investigation in inflammatory disorders. Pharmacological 
studies were conducted to investigate the potency of CXCR1/
CXCR2 inhibition for the prevention of inflammation- and 
autoimmunity-mediated damage of pancreatic islets. Blockade 
of CXCR1/CXCR2 was associated with inhibition of insulitis 
and modification of leukocytes distribution in blood, spleen, 
bone marrow, and lymph nodes, and was effective in preventing 
diabetes in an inflammation-mediated model based on multiple 
low dose injections of streptozotocin and in preventing diabetes 
in NOD mice (58). Pharmacokinetic, toxicological, and pharma-
codynamic data have reinforced the therapeutic clinical potential 
of Ladarixin, and a Phase II clinical study to test ladarixin at the 
onset of type 1 diabetes has been recently activated with the aim 
to confirm this strategy and further investigate its potential in 
preserving residual β-cell function.
ALLOSTeRiC MODULATiON OF 
CLASSiCAL CHeMOATTRACTANT 
ReCePTORS
The complement has long been recognized as a potentially useful 
therapeutic target, and a number of strategic approaches and 
therapeutic agents have been developed during the last years (see 
Table 1) (59, 60). Inhibition of complement activation has been 
approached with low molecular weight natural and synthetic 
compounds, polypeptides, and macromolecules; nevertheless, 
to place in the market, a complement-directed drug resulted 
more challenging than expected. Eculizumab, a humanized mAb 
against C5, was approved for the treatment of rare disorders only 
in 2007, then followed in 2008 by the approval of nanofiltered 
C1 inhibitor, and by the orphan drug designation for the human 
mAb OMS721 targeting mannan-binding lectin-associated 
serine protease-2. C5 and its GPCR C5aR have been the main 
targets for the inhibition of complement activation, with two 
molecules that have reached clinical stage. In Phase I clinical trials 
in rheumatoid arthritis and psoriasis, the C5aR cyclic peptidomi-
metic antagonist PMX-53 (Cephalon, now Arana) was found safe 
and well tolerated, and able to block C5aR at a stage in immune 
and inflammatory processes earlier than other current anti- 
inflammatory drugs, but has been discontinued in 2012 due to 
poor pharmacokinetic profile and off-target side effects. CCX-168 
(now avacopan) ChemoCentrix is an orally administered C5aR 
inhibitor under development for various autoimmune disorders, 
including ANCA-associated vasculitis, atypical hemolytic uremic 
syndrome, and IgA nephropathy. Recently, positive top-line data 
from CCX-168 Phase II CLEAR trial have been announced in 
patients with ANCA-associated vasculitis, paving the way for a 
Phase III trial announced to start within 2016. At the same time, 
other Phase II trials in rare and orphan indications are ongoing 
(Thomson Reuters Cortellis Business Intelligence; https://cortel-
lis.thomsonreuterslifesciences.com).
Among molecules still at a preclinical stage, DF2593A repre-
sents an interesting case of study on the topic of GPCR allosteric/
regulatory sites. Our studies on C5aR were guided by the hypoth-
esis that a minor allosteric pocket conserved across the TM region 
of the chemoattractant receptor family could represent a “trigger-
ing domain” crucial for the fine tuning of receptor activation (61). 
This pocket spanning between TM 1, 3, 6, and 7 was the same 
reported as the binding site of reparixin and ladarixin. Despite 
the low homology between C5aR, CXCR1, and CXCR2, the key 
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features of the minor pocket were found conserved, thus allowing 
the rational design of DF2593A as a putative high affinity selec-
tive ligand of C5aR. Extensive mutagenesis studies confirmed the 
mechanistic hypothesis showing that this region, as observed for 
CXCR1 and CXCR2, is not involved in orthosteric ligand biding 
but essential for intracellular signal transduction and receptor 
function (61). DF2593A was shown effective in several animal 
models of acute and chronic inflammatory and neuropathic pain 
(61), and is currently under evaluation as a potential clinical 
candidate in these indications. These studies further confirm the 
great potential of allosteric modulation as a promising strategy 
to generate potent and selective modulators of chemoattractant 
receptors.
ALLOSTeRiC MODULATORS: New 
OPPORTUNiTieS FOR DRUG DiSCOveRY
Studies on allosteric ligands with different binding properties at 
cognate GPCRs have led to a substantial increase in our under-
standing of GPCR pharmacology, thus smoothing the way to the 
design of safer, better-tolerated, and more efficacious drugs. The 
recent advances in GPCR structure biology, with the elucidation 
of several high resolution crystal structures of GPCRs [references 
in Ref. (62)], will give a further significant boost to this complex 
and stimulating research field (62), offering new tools for the 
rational design of allosteric modulators.
As thoroughly discussed, allosteric GPCR modulators present 
unique advantages as compared to orthosteric ligands, mostly by 
virtue of their high receptor subtype selectivity and functional 
selectivity. The first characteristic relies on the greater divergence 
in the amino acid sequence of allosteric sites between receptor 
subtypes. While functionally conserved, allosteric sites apparently 
evolved under a lower evolutionary pressure as compared to the 
orthosteric sites involved in the recognition of the endogenous 
ligand. The functional selectivity and probe-dependence proper-
ties of many allosteric modulators are intrinsically associated with 
ability of these molecules to fine tune the dynamic conformational 
rearrangement of the receptor and ligand/receptor complexes. 
This second level of selectivity may offer unprecedented oppor-
tunities for the design of tailored pharmacological tools but also 
implicates a profound evolution of the drug discovery process 
demanding for a deep in vitro characterization of the new lead 
candidates for a correct interpretation of in vivo studies results. 
A fascinating aspect of this research field originates from the 
continuous mutual feedback between drug discovery and recep-
tor biology research: in a virtuous circle, new lead candidates 
stemmed from medicinal chemistry programs become important 
research tools useful to improve the knowledge of GPCR struc-
ture and function that fundamentally influence the drug design 
and development process.
From the drug discovery point of view, allosteric modulators 
may provide functional advantages over classical orthosteric 
agonists and antagonists (63). First, as allosteric modulators do 
not compete with endogenous ligands, their effect on GPCRs is 
saturable, meaning that when all allosteric sites are occupied no 
more effects are achieved. Second, as allosteric ligands modulate 
activities of endogenous ligands engaging the orthosteric site, 
their influence on receptors’ conformation and signaling will 
be evident only when the endogenous ligand is present. Third, 
NAMs often show only partial antagonist activity without exhib-
iting any agonist activity (64), thus suggesting that a partial NAM 
could have a greater safety index than a full antagonist. Also 
for PAMs, the above described ligand-dependent activity may 
improve safety profile, due to the fact that normal physiological 
regulation of signaling, including temporal regulation, remains 
unchanged (65).
The multifactorial interactions implicated in chemoattract-
ant biology make very difficult to predict the in vivo behavior 
of allosteric ligands in pathological conditions, and a deep 
in  vitro characterization in different conditions is absolutely 
required for the interpretation of the results of pharmacological 
studies. Antagonist affinities can vary depending on the agonist, 
the presence or absence of allosteric ligands, the specific site 
through which the effect is exerted, and the specific signaling 
under consideration. Since most GPCRs can engage different 
downstream signaling pathways, which are often cell-, tissue-, 
and/or context-specific, it is crucial to take into account the 
entire signaling repertoire for the drugs of reference in normal 
vs. pathological conditions. Future research efforts should be 
oriented toward the development of approaches aiming to eluci-
date the full spectrum of ligand signaling in different cell models 
and able to integrate new screening and quantitative analytical 
methods, with the aim to link these signaling signatures to 
preclinical or clinical data.
CONCLUSiON
The discovery of allosteric modulators has represented a pro-
found advance in the research of drugs acting on chemoattract-
ant receptors, and over the last years, several NAMs and PAMs 
of both chemoattractant receptors belong to both classical che-
moattractant (Cinacalcet, PAM of CaSR of PTH) and chemokine 
GPCRs (Reparixin, NAM of CXCR1; Ladarixin NAM of CXCR1/
CXCR2; and Navarixin, NAM of CXCR2) entered clinical trials, 
and in some cases, successfully reached the market (Maraviroc, 
NAM of CCR5; Plerixafor, NAM of CXCR4). The pharmaco-
logical implications potentially deriving from the availability of 
multiplicity of molecules that, acting through a single receptor, 
differentially regulate its signaling activity are still far from being 
fully exploited and will offer opportunities for the development 
of new drugs targeting chemoattractant receptors in the near 
future.
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